Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Sammons, Sarah L.
Meisel, Jane
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Isakoff, Steven J.
    Kuba, Maria Gabriela
    Sanders, Melinda
    Forero-Torres, Andres
    Yap, Jeffrey T.
    Van Den Abbeele, Annick D.
    Li, Yisheng
    Arteaga, Carlos L.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
    Finn, Richard S.
    Crown, John
    Lang, Istvan
    Kulyk, Sergey O.
    Schmidt, Marcus
    Patel, Ravi
    Thummala, Anu
    Bondarenko, Igor
    Randolph, Sophia
    Kim, Sindy
    Huang, Xin
    Donnelly, Erling
    Bartlett, Cynthia Huang
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
    Kristoffer B. Kristensen
    Ida Marie Nedergaard Thomsen
    Tobias Berg
    Annette R. Kodahl
    Anders Bonde Jensen
    Breast Cancer Research and Treatment, 2021, 188 : 799 - 809
  • [45] Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC) in clinical practice: A real-world multi-country survey
    Cardoso, Fatima
    Rihani, Julie
    Aubel, Dawn
    Moore, Adam
    Harmer, Victoria
    Harbeck, Nadia
    Casas, Ana
    Haftchenary, Sina
    Pathak, Purnima
    Schumacher-Wulf, Eva
    CANCER RESEARCH, 2022, 82 (04)
  • [46] REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN ER+/HER2-METASTATIC BREAST CANCER: RESULTS FROM A MULTICOUNTRY RETROSPECTIVE MEDICAL RECORD REVIEW
    Mitra, D.
    Kurosky, S.
    Zanotti, G.
    Kaye, J. A.
    VALUE IN HEALTH, 2016, 19 (03) : A137 - A137
  • [47] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
    Damodaran, Senthil
    Moore, Halle
    O'Sullivan, Ciara C.
    Plourde, Paul V.
    Riordan, Gary
    Sloane, Hillary S.
    Tripathy, Debu
    Carroll, Dominic
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [49] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study
    Goetz, Matthew P.
    Gal-Yam, Einav
    Stover, Daniel
    Sammons, Sarah L.
    Graff, Stephanie L.
    Wang, Grace
    Cristofanilli, Massimo
    Riordan, Gary
    Sloane, Hillary S.
    Carroll, Dominic
    Plourde, Paul V.
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2- Breast Cancer: A Multicountry Retrospective Medical Record Review
    Kurosky, Samantha K.
    Mitra, Debanali
    Zanotti, Giovanni
    Kaye, James A.
    CLINICAL BREAST CANCER, 2018, 18 (04) : E529 - E538
12345